NovaBay Pharmaceuticals Approves Issuance of 837 Million Shares and 2026 Equity Incentive Plan in Shareholder Vote

NovaBay Pharmaceuticals shareholders approved significant corporate changes, including an increase in authorized common shares from 1.5 billion to 5 billion and the issuance of over 843 million new shares from private placements. The company also adopted a new 2026 Equity Incentive Plan and made amendments to its Certificate of Incorporation, removing the prohibition on stockholder action by written consent and adding officer exculpation. These changes have substantial implications for existing shareholders, including potential dilution.